

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. For patients who experience disease progression on a CDK4/6 inhibitor with endocrine therapy for ER-positive metastatic breast cancer (mBC), testing is indicated for alterations in which of the following genes?**
 - a. ESR1
 - b. PIK3CA
 - c. Both a and b**
 - d. Neither a nor b
- 2. Which of the following drug classes best describes the mechanism of action of imlunestrant?**
 - a. Antibody-drug conjugate
 - b. Microtubule inhibitor
 - c. Oral selective estrogen receptor degrader (SERD)**
 - d. Selective androgen receptor modulator
- 3. The Phase III SERENA-6 trial is currently investigating the next-generation oral SERD camizestran in combination with CDK4/6 inhibition for which subset of patients with breast cancer?**
 - a. Those with newly diagnosed localized breast cancer
 - b. Those with advanced breast cancer whose disease progressed on prior fulvestrant or an investigational SERD
 - c. Those with HR-positive, HER2-positive, ESR1 wild-type advanced breast cancer
 - d. Those with HR-positive, HER2-negative advanced breast cancer with ESR1 mutations**
- 4. Which grade of interstitial lung disease would lead to permanent discontinuation of treatment with trastuzumab deruxtecan?**
 - a. Grade 1
 - b. Grade 2**
 - c. Grade 3
 - d. Grade 4
- 5. Which of the following genes is the target of datopotamab deruxtecan?**
 - a. NRG1
 - b. MET
 - c. CEACAM5
 - d. TROP2**